REN Stock Analysis: Relx | AS
Specialty Business Services | AS, Netherlands | Market Cap: 48.844m EUR | 12M Return: -35.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 35.5M
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RELX PLC is a UK-headquartered information services company, founded in 1903, that provides analytics and decision tools for professional and business customers across North America, Europe, and international markets. Originally known as Reed Elsevier PLC, it adopted the RELX name in July 2015. The business operates through four segments: Risk (risk analytics and commercial healthcare products), Scientific, Technical & Medical (scientific and medical data sets), Legal (legal, regulatory, and business information and analytics), and Exhibitions (digital and in-person event tools).
RELX operates a primarily B2B subscription and data analytics model serving regulated professional markets such as insurance, science, healthcare, and law, with the Exhibitions segment adding physical and virtual events to the portfolio. The company is classified under the Industrials sector within the Diversified Support Services sub-industry.
- Risk segment analytics subscriptions drive recurring revenue growth
- Exhibitions revenue rebounds as trade show activity normalizes globally
- Share buybacks and pricing power support margin expansion outlook
| Net Income: 2.07b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 5.25 > 1.0 |
| NWC/Revenue: -31.64% < 20% (prev -28.85%; Δ -2.78% < -1%) |
| CFO/TA 0.19 > 3% & CFO 2.87b > Net Income 2.07b |
| Net Debt (7.30b) to EBITDA (3.69b): 1.98 < 3 |
| Current Ratio: 0.49 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.83b) vs 12m ago -3.30% < -2% |
| Gross Margin: 63.69% > 18% (prev 65.02%; Δ -1.33% > 0.5%) |
| Asset Turnover: 64.17% > 50% (prev 62.34%; Δ 1.83% > 0%) |
| Interest Coverage Ratio: 10.46 > 6 (EBIT TTM 3.02b / Interest Expense TTM 289.1m) |
| DSRI: 0.98 (Receivables 2.47b/2.47b, Revenue 9.59b/9.43b) |
| GMI: 1.02 (GM 65.02% / 63.69%) |
| AQI: 1.00 (AQ_t 0.79 / AQ_t-1 0.79) |
| SGI: 1.02 (Revenue 9.59b / 9.43b) |
| TATA: -0.05 (NI 2.07b - CFO 2.87b) / TA 14.8b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at EUR 29.22 with a total of 1,360,570 shares traded. Over the past week, the price has changed by +4.28%, over one month by +2.45%, over three months by +3.13% and over the past year by -35.23%.
Current recommended Stop Loss: 27.90 (which is 4.5% or 1.5 ATR below the current price).
Relx has no consensus analysts rating.
Market Cap GBP = 41.6b (48.8b EUR * 0.8517 EUR.GBP)
P/E Trailing = 21.4769
P/E Forward = 16.9779
P/S = 5.0933
P/B = 17.9494
P/EG = 1.3058
Revenue TTM = 9.59b GBP
EBIT TTM = 3.02b GBP
EBITDA TTM = 3.69b GBP
Long Term Debt = 5.63b GBP (from longTermDebt, last quarter)
Short Term Debt = 1.60b GBP (from shortTermDebt, last quarter)
Debt = 7.44b GBP (from shortLongTermDebtTotal, last quarter) + Leases 97.0m
Net Debt = 7.30b GBP (calculated: Debt 7.44b - CCE 131.1m)
Enterprise Value = 48.9b GBP (41.6b + Debt 7.44b - CCE 131.1m)
Interest Coverage Ratio = 10.46 (Ebit TTM 3.02b / Interest Expense TTM 289.1m)
EV/FCF = 17.17x (Enterprise Value 48.9b / FCF TTM 2.85b)
FCF Yield = 5.82% (FCF TTM 2.85b / Enterprise Value 48.9b)
FCF Margin = 29.69% (FCF TTM 2.85b / Revenue TTM 9.59b)
Net Margin = 21.53% (Net Income TTM 2.07b / Revenue TTM 9.59b)
Gross Margin = 63.69% ((Revenue TTM 9.59b - Cost of Revenue TTM 3.48b) / Revenue TTM)
Gross Margin QoQ = 61.19% (prev 66.25%)
Tobins Q-Ratio = 3.31 (Enterprise Value 48.9b / Total Assets 14.8b)
Interest Expense / Debt = 3.89% (Interest Expense 289.1m / Debt 7.44b)
Taxrate = 24.44% (672.2m / 2.75b)
NOPAT = 2.28b (EBIT 3.02b * (1 - 24.44%))
Current Ratio = 0.49 (Total Current Assets 2.96b / Total Current Liabilities 6.00b)
Debt / Equity = 3.14 (Debt 7.44b / totalStockholderEquity, last quarter 2.37b)
Debt / EBITDA = 1.98 (Net Debt 7.30b / EBITDA 3.69b)
Debt / FCF = 2.56 (Net Debt 7.30b / FCF TTM 2.85b)
Total Stockholder Equity = 2.81b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.82% (Net Income 2.07b / Total Assets 14.8b)
RoE = 73.51% (Net Income TTM 2.07b / Total Stockholder Equity 2.81b)
RoCE = 35.82% (EBIT 3.02b / Capital Employed (Equity 2.81b + L.T.Debt 5.63b))
RoIC = 22.31% (NOPAT 2.28b / Invested Capital 10.2b)
WACC = 6.15% (E(41.6b)/V(49.0b) * Re(6.73%) + D(7.44b)/V(49.0b) * Rd(3.89%) * (1-Tc(0.24)))
Discount Rate = 6.73% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -2.44%
[DCF] Terminal Value 77.97% ; FCFF base≈2.56b ; Y1≈2.93b ; Y5≈4.32b
[DCF] Fair Price = 32.95 (EV 65.0b - Net Debt 7.30b = Equity 57.6b / Shares 1.75b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 99.27 | Revenue CAGR: 2.35% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.66 | Chg30d=+0.06% | Revisions=+25% | GrowthEPS=+12.8% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=1.87 | Chg30d=+0.06% | Revisions=+25% | GrowthEPS=+12.6% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: +40% (up=2, down=0)